Parkinson's disease (PD) and Huntington's disease (HD) 
Introduction

Parkinson's disease (PD) is a chronic progressive neurodegenerative disorder [1] that exhibits increasing prevalence with aging.
On average, it affects about 2 in 1000 people [2] [3] [4] . Only about 10% of the cases reveal a familial background; the remaining 90% are considered to be sporadic with uncertain aetiology, which draws attention to the role of possible environmental risk factors [6] ). The main underlying pathological hallmark is a preferential loss of brain stem catecholaminergic, and especially mesencephalic dopaminergic neurons in the substantia nigra pars compacta (SNpc) and the development of intracellular inclusions called Lewy bodies [7] .
(reviewed in [5]). The main clinical features of PD, including resting tremor, rigidity, brady-and hypokinesia and postural instability, develop in consequence of the complex dysfunction of the motor network, with crucial roles for the alterations in the basal ganglia circuits (reviewed in
The resulting dopamine deficiency, apparent mainly in the striatum, means that the brain is no longer capable of sufficient motor function control (reviewed in [6]).
Huntington's disease (HD) is likewise a chronic progressive neurodegenerative disease [8] , observed in the middle-aged. In contrast with PD, it is genetically determined by an autosomal dominantly inherited definite single mutation in the IT15 gene coding for the huntingtin protein [9] . The prevalence of HD is rather low relative to that of PD; it affects only about 5 in 100,000 people [10] [11] [12] [13] . The clinical features of HD are characterized by cognitive, psychiatric and motor symptoms (reviewed in [14, 15] ). [18] . The loss of ␥-aminobutyric acidergic (GABAergic) mediumsized spiny neurons (MSNs) in the striatum (caudate nucleus ϩ putamen) is the most pronounced feature [19] [20] [21] , resulting in a dysfunction of the basal ganglia circuits, and leading to the development of the characteristic symptoms (reviewed in [22] ).
In view of the motor symptoms, the typical loss of coordination of the voluntary movements and the appearance of involuntary movements (such as chorea and dystonia) evolve. Further, a progressive gait impairment also develops, manifested in brady-and hypokinesia [16, 17]. The pathological alterations are mainly seen in the central nervous system (CNS), and especially in the caudate nucleus, the putamen and the deeper layers of the cerebral cortex
The role of mitochondrial impairment and oxidative stress in neurodegeneration Background
The mitochondria take part in both physiological and pathological processes, such as energy supply, signalling, Ca 2ϩ -homeostasis, cell cycle regulation, apoptosis, free radical generation, thermogenesis, development and aging (reviewed in [23, 24] ; Fig. 1 (Fig. 1) Neuroactive kynurenines: sites of action
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sequestration with a consequential impairment of the mitochondrial function, ER stress, pathological overactivation of several types of kinases and/or phosphatases, proteases (e.g. caspases and calpains), neuronal nitric oxide synthase (nNOS), endonucleases, phospholipases and transglutaminases, leading to detrimental effects (reviewed in [77]).
Parkinson's disease
A recently published paper [78] dealing with the dysregulation of glutamate homeostasis in the mouse SNpc due to chronic MPTP treatment provided evidence of glutamate excitotoxicity involvement in PD pathogenesis secondary to a mitochondrial dysfunction (commented in [79]). Neurons in the SNpc possess glutamate receptors and receive glutamatergic input from the subthalamic nucleus (the main input), cerebral cortex, amygdala and pedunculopontine and laterodorsal tegmental nuclei (reviewed in [80]). The metabolic compromise leads to a decrease in striatal dopaminergic innervation, resulting in overactivation of the subthalamic nucleus. This causes an increase in glutamate release onto the compromised dopaminergic neurons in the SNpc (reviewed in [81]). Hence, the excitotoxic cascade further worsens the neurodegenerative process, inducing a vicious cycle.
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3). As regards the role of kynurenines in the CNS, it is important to highlight that L-KYN is present in the
KYNA exerts broad-spectrum endogenous antagonism on ionotropic excitatory amino acid receptors [135] (Fig. 2). In micromolar concentrations, it acts as a competitive antagonist at the strychnine-insensitive glycine-binding site of the NMDAR [136] and displays weak antagonistic effects on the AMPARs and kainate
receptors [137] . KYNA has been found to be capable of facilitating AMPAR responses in low (nanomolar to micromolar) concentrations [138] , but the concentration range is controversial: KYNA in micromolar concentrations has recently been shown to have neuroinhibitory effects, whereas in nanomolar concentrations it was claimed to be a facilitator [139] . In addition to its direct effects on glutamate receptors, KYNA non-competitively blocks the ␣7-nicotinic acetylcholine receptors [140] , presynaptic activation of which is involved in the regulation of glutamate release [141] . It has been reported that, through activation at the G protein-coupled receptor GPR35, KYNA can elicit IP3 production and Ca 2ϩ mobilization [142] , [143] . QUIN is a weak, but specific competitive agonist of the NMDAR subgroup containing the NR2A and NR2B subunits, with low receptor affinity [144] . There are 2 mechanisms via which it can cause excitotoxicity modulating the glutamatergic system: the direct activation of NMDARs [145] or the release and uptake inhibition of glutamate [146, 147] (Fig. 2) . The production of ROI [148] and lipid peroxydation due to QUIN also contribute to its neurotoxic effects [149] . The deleterious effects of 3-OH-L-KYN are mediated by free radicals and not glutamate receptors [150, 151] (Fig. 2) . Some of its detrimental actions may be due to its metabolite, 3-hydroxyanthranilic acid, which readily undergoes auto-oxidation with the production of O2 Ϫ [152] , and it has also been shown to be neurotoxic [153] .
but the role of this phenomenon is questionable as regards the CNS, because GPR35 exhibits a limited expression in the brain and a relatively high KYNA concentration is necessary for activation. With respect to the KATs, it is interesting that the neuronal expression of KAT-I appears to have effects on developmental processes, such as programmed cell death
Neuroactive kynurenines in neurodegenerative disorders
Parkinson's disease [176] , and in a cellular toxin model of PD [177] . Although L-carnitine suppresses 3-NP-induced MPT [178] , and is neuroprotective in a transgenic mouse model of HD [179] , low-dose acetyl-L-carnitine administration in a double-blind, placebo-controlled study showed no benefit [180] .
L-carnosine
L-carnosine (␤-alanyl-L-histidine) is a dipeptide with demonstrated antioxidant, antiglycator and metal chelator properties (reviewed in [181]). In a pilot study, L-carnosine increased the efficacy of L-DOPA treatment in PD patients [182]. In a transgenic mouse model of HD, L-carnosine was unable to improve the survival or the motor performance of mice significantly (our unpublished data).
Coenzyme Q 10
Coenzyme Q10 is a lipid-soluble benzoquinone that functions as an electron transporter in the ETC and as an antioxidant. Coenzyme Q10
has also been demonstrated to be effective in the MPTP model of PD [183] and in the transgenic mouse models of HD [184, 185] . Whereas low-dose administration was ineffective [186] [190] . This might be due to underdosing; the Pre2CARE study has revealed that higher doses of coenzyme Q10 are reasonably well tolerated [191] .
A larger study (2CARE) is currently ongoing for the re-evaluation of coenzyme Q10 in HD.
Creatine
Creatine kinase and its substrates creatine and phosphocreatine take part in the buffering of intracellular energy reserves (reviewed in [192] ) and in the inhibition of MPT activation [193] . The exogenous administration of creatine proved effective in the MPTP model of PD [194] and the 3-NP, malonate [195] and transgenic mouse models [196, 197] [198, 199] and a placebo-controlled randomized pilot trial [200] 
of HD. Nevertheless, a randomized, doubleblind phase II trial in early PD
did not indicate any robust clinical benefit. A phase III, long-term (5 year follow-up), multicentre, double-blind, placebo-controlled study [The National Institutes of Health Exploratory Trials in Parkinson Disease Long-term Study 1 (NET-PD LS1)] is currently ongoing. As regards HD, creatine was not found to be significantly effective either in a 2 year open label
pilot study [201, 202] or in a placebo-controlled pilot trial [203] [204, 205] . Its oxidized form, cystamine, exerts a transglutaminase inhibitory effect (reviewed in [206] ). An early study was unable to detect any protective effect of cysteamine in the MPTP model [207] , but it has recently been proved that lower doses of both cysteamine and cystamine show efficacy [208, 209] . Treatment with cystamine afforded neuroprotection in transgenic mouse models of HD [210] [211] [212] . [213] . [215] and is beneficial in a transgenic mouse model of HD [216] . A randomized, doubleblind, placebo-controlled study also demonstrated beneficial effects [217] . [226] . [207, 229] , and in PD patients in the large, randomized, placebo-controlled Deprenyl And Tocopherol Antioxidative Therapy Of Parkinsonism (DATATOP) study [230] . However, it has also been shown that ␣-tocopherol is capable of attenuating 6-hydroxydopamine lesions [231] and iron-induced nigral neuron loss [232] . Furthermore, a pilot trial of high-dose ␣-tocopherol and ascorbate demonstrated beneficial effects in PD patients [233] . Nevertheless, a double-blind, placebo-controlled study did not confirm the efficacy of high-dose ␣-tocopherol in HD patients, though it would be beneficial for patients early in the course [234] . Interestingly, ␥-tocopherol (the predominant form of vitamin E in the diet) effected a considerably larger attenuation than the statistically ineffective ␣-tocopherol as concerns MPTPinduced dopamine loss [235] . [238, 239] , it is mainly used in combination with probenecid to achieve neuroprotection (e.g. in a migraine model: [240] [245] . To overcome these disadvantages, numbers of KYNA derivatives have been synthetized with preserved or enhanced pharmacodynamic properties (reviewed in [246] [247] [248] [253] . A newly synthesized KYNA amide, previously proved to be beneficial in migraine [254] and epilepsy [255] models, exerts neuroprotection in a transgenic mouse model of HD [256] . 
Cysteamine/cystamine
Cysteamine, an antioxidant, is capable of the prevention of lipid peroxidation and can exert beneficial effects through its action on enzymes responsible for the maintenance of an antioxidant milieu or energy preservation
A phase I dose finding and tolerability study [Phase I dose finding and tolerability study of cysteamine (Cystagon) in Huntington's disease (CYTE-I-HD)] has already been carried out with cysteamine in HD patients
Eicosapentaenoic acid
Eicosapentaenoic acid (EPA) is an essential n-3 polyunsaturated fatty acid that targets the mitochondrial function, especially by acting on peroxisome proliferator activated receptors (reviewed in [214]). It has been shown that the administration of polyunsaturated fatty acid mixtures containing EPA improves dyskinesias and reverses weight loss in HD patients
Taurine
Taurine is a ␤-amino acid with antioxidant properties (reviewed in [227]). Although it has been found to be protective in the 3-NP model of HD [228], we did not observe any beneficial effects either in the MPTP model of PD, or in a transgenic mouse model of HD (our unpublished data).
Tocopherol
␣-tocopherol (the predominant form of vitamin E in the tissues and in supplements) is a lipid-soluble antioxidant which, despite the great expectations, was reported to be ineffective both in animal MPTP models of PD
L-KYN/KYNA
Concluding remarks
